ME (23andMe Inc.) יתרות המזומנים של החברה

23andMe Holding Co. (ME) dominates the personal genomics segment, leveraging massive datasets to develop new drugs. This cash liquidity chart on GURU.Markets reflects funding dynamics, where the indicator is fixed at 0.06. This is supported by global brand trust in DNA research and the implementation of cloud-based AI models for the precise analysis of genetic risks for millions of users.
פילוחים אנליטיים ודוחות נתונים של חברת 23andMe Holding Co (ME)

Liquidity determines a business's ability to sustain operational activities without external borrowing. This indicator measures the volume of available cash, which serves as a guarantee of solvency and a resource for growth. For 23andMe Holding Co. (ME), this is critical due to the loss-making nature of the pharma sector and declining demand for tests. A shortage of reserves amplifies risks in the event of potential data breaches. The dynamics of these processes are reflected in this cash reserves chart.